"You are neither an interested party nor an affected party," Justice Vibhu Bakhru said and dismissed the application of All India Drug Action Network (AIDAN) which was seeking to intervene in the petition filed by an organisation of drug manufacturers opposing NPPA's notification.
The Organisation of Pharma Producers of India's (OPPI) has challenged NPPA's notification putting a cap on the prices of drugs which do not fall under the National List of Essential Medicines (NLEM).
The matter is still pending before the apex court, AIDAN said.
NPPA had on July 10 brought prices of over 100 non-scheduled drugs under price control as per paragraph 19 of Drug Prices Control Order (DPCO).
Also Read
Paragraph 19 of DPCO, 2013, authorises the NPPA in extraordinary circumstances, if it considers necessary so to do in public interest, to fix the ceiling price or retail price of any drug for such period as it deems fit.
It had also said that as per the government's drug policy regime, prices of non-scheduled drugs are to be monitored, not fixed.
While bringing these drugs under price control, the NPPA has noted that it is of the considered view that there exists huge inter-brand price differences in branded-generics/off patent drugs, which is indicative of a severe market failure.